RxDoctor Payments Data

Valerie Rasberry, MD

Family Medicine · Palm City, FLNPI 1053707323

Payments from drug & device makers

$5,308in general payments, 2019–2025

Across 66 payments — averaging $80.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$734
  • Amgen$486
  • AbbVie$339
  • Lilly USA, LLC$315
  • plus $745 from 7 others

What the payments were for

  • Food & beverage$5,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,308 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$105,820
Medicare patients
697
Services billed
2,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$52,419
XareltoRivaroxaban36$43,148
JanuviaSitagliptin Phosphate36$42,650
OzempicSemaglutide40$41,021
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$30,188
Breo ElliptaFluticasone/Vilanterol35$22,295
MounjaroTirzepatide13$15,648
TrulicityDulaglutide14$14,780
MyrbetriqMirabegron12$13,725
SynthroidLevothyroxine Sodium139$12,067
Levothyroxine Sodium606$6,257
Atorvastatin Calcium572$5,637
Rosuvastatin Calcium526$5,317
Tresiba Flextouch U-100Insulin Degludec12$4,266
Incruse ElliptaUmeclidinium Bromide12$4,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$734$56,55883 claims
Johnson & JohnsonXarelto$122$43,14836 claims
MerckJanuvia$125$42,65036 claims
Novo NordiskOzempic$1,156$41,02140 claims
Lilly USA, LLCMounjaro, Trulicity$315$30,42827 claims
AbbVieSynthroid$339$12,067139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palm City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →